Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based Suven Life Science has received three patents from Australia and one patent from New Zealand covering new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
Subscribe to our email newsletter
The issued patents cover the class of selective 5-HT compounds of Suven that are being developed to treat cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
Suven CEO Venkat Jasti said they are very pleased by the grant of these patents to Suven for their pipeline of molecules in CNS arena that are being developed for cognitive disorders.